Detalles de la búsqueda
1.
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
J Am Acad Dermatol
; 86(3): 581-589, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252464
2.
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Dermatol Ther
; 34(2): e14808, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33491259
3.
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Pharmacoecon Open
; 6(6): 871-880, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155891
4.
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Dermatol Ther (Heidelb)
; 12(12): 2797-2815, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36331713
5.
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
J Manag Care Spec Pharm
; 28(2): 206-217, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35098751
6.
Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study.
ACR Open Rheumatol
; 3(12): 879-887, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34550647
7.
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Dermatol Ther (Heidelb)
; 11(6): 2133-2145, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652590
Resultados
1 -
7
de 7
1
Próxima >
>>